Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy

AIDS

Volumn 13, Issue 11, 1999, Pages

  Piketty, Christophe ^a   Race, Esther ^b   Castiel, Philippe ^a   Belec, Laurent ^a   Peytavin, Gilles ^b   Si Mohamed, Ali ^a   Gonzalez Canali, Gustavo ^c   Weiss, Laurence ^a   Clavel, François ^b   Kazatchkine, Michel D ^a  

^a HÔPITAL BROUSSAIS   (France)

^b BICHAT HOSPITAL   (France)

^c SAINT JOSEPH HOSPITAL   (France)

Author keywords

Efavirenz; Genotypic mutations; Phenotypic resistance; Protease inhibitors; Saquinavir

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; GENOTYPE; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LYMPHOCYTE COUNT; MALE; PHENOTYPE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VERTIGO; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TREATMENT OUTCOME;

EID: 0032839921     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907300-00001     Document Type: Article

References (28)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
2. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
3. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
4. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
5. Piketty C, Castiel P, Belec I, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12:745-750.
6. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723-724.
7. Zimmerli S, Paris D, Lederberger B. Incidence and predictors factors of virologic failure of antiretroviral triple drug therapy in a community based cohort. 12th World AIDS Conference. Geneva, July 1998 [abstract 22349].
8. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
9. Lerner BH, Gulick RM, Neveloff Dubler N. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998, 129:573-578.
10. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
11. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
12. Boucher C. Rational approaches to resistance: using saquinavir. AIDS 1996, 10 (suppl 1):S15-S19.
13. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998, 279:1984-1991.
14. Hertogs K, Mellors J, Schel P, et al. Patterns of cross-resistance among protease inhibitors in over 500 clinical HIV-1 isolates. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 395].
15. Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir and saquinavir in protease inhibitor-naive patients in year two of follow-up. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstact 388].
16. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
17. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 1997, 11:F95-F99.
18. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
19. Tebas P, Patrick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelvinavir. AIDS 1999, 13:F23-F28.
20. Landman R, Peytavin G, Leibowitch J, et al. Ritonavir low dosages increases dramatically the saquinavir bioavailability: A PK study in healthy volunteers. 12th World AIDS Conference. Geneva, July 1998 [abstract 42257].
21. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994, 241:651-662.
22. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998, 72:3300-3306.
23. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy. Edited by Chou TC, Rideout J. Orlando: Academic Press; 1991:61-102.
24. Schinazi RF, Larder BA, Mellors JW. Resistance table: mutations in retroviral genes associated with drug resistance, Int Antiviral News 1997, 5:129-142.
25. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
26. Kaufmann GR, Duncombe C, Cunningham P, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998, 12:1625-1630.
27. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998, 12:619-624.
28. Harrigan R, Hogg R, Yip B, et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract 1-78].